Providence, RINCT05442216Now EnrollingIRB Ready

Acute Myeloid Leukemia Clinical Trial in Providence, RI

Access cutting-edge acute myeloid leukemia treatment through this clinical trial at a research site in Providence. Study-provided care at no cost to qualified participants.

Sponsored by Joshua Zeidner

Quick Self-Assessment

See if you qualify for this Providence location

Preparing your pre-screening questions...

Expert Care in Providence

Access acute myeloid leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukemia treatment provided free

Apply for This Providence Location

Check if you qualify for this acute myeloid leukemia clinical trial in Providence, RI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Providence

    Convenient for RI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Providence site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukemia Study in Providence

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to exceed 10 days if postponement is required to allow for toxicity resolution). Subjects with a marrow CR (See the protocol) after Cycle 2 will continue Tagraxofusp for Cycles 3 to 12 (up to 1 year of treatment) at 12 mcg/kg IV for 5 consecutive days every 28 days. In subjects without a marrow CR aft

Sponsor: Joshua Zeidner

Who Can Participate

Inclusion Criteria

Subject must meet all of the following applicable inclusion criteria to participate in this study:
Subjects must have newly diagnosed, untreated AML, as defined by ≥ 20% blasts in peripheral blood or bone marrow by manual aspirate differential, immunohistochemistry staining, or flow cytometry, as defined by standard WHO 2016 diagnostic criteria.
Subjects must have documented CD123 positivity on leukemia cells by a centralized flow cytometry assay (Hematologics).
Documented diagnosis of prior MDS, CMML, MDS/MPN overlap syndromes, or MPN's according to WHO criteria. Subjects must have received at least 2 cycles of hypomethylating agents (azacitidine or decitabine or oral decitabine/cedazuridine) for the management of MDS, CMML, MDS/MPN overlap syndromes, or MPN's. NOTE: Subjects who have enrolled on clinical trials with investigational agents in combination with HMA's will still be eligible. Investigational agents must have been discontinued \>21 days prior to

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Providence?

Yes, this clinical trial (NCT05442216) has an active research site in Providence, RI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukemia Treatment Options in Providence, RI

If you're searching for acute myeloid leukemia treatment options in Providence, RI, this clinical trial (NCT05442216) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Providence research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Providence, RI

See all leukemia clinical trials recruiting in Providence — not just this study.

Browse Leukemia Trials in Providence

Ready to Join in Providence?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Providence, RI